Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences, Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life and resolve serious unmet medical needs, self-described.

Summit Therapeutics

Avidity Biosciences develops targeted RNA therapeutics using its Antibody Oligonucleotide Conjugates platform. The company is focused on addressing unmet patient needs across various therapeutic areas.

Metric
Company Name	Avidity Biosciences, Inc.	Ardelyx, Inc.	Summit Therapeutics
Symbol	RNA	ARDX
MSH ID	COM:AVIDITYBIOSCIENCES	COM:ARDELYX	COM:SUMMITTHERAPEUTICS
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US
Stage		Debt	Post-IPO Equity
Employee Count	253	267
Website	aviditybiosciences.com	ardelyx.com	summittherapeutics.com
LinkedIn
Founders

Metric
Market Cap	4.07B	1.30B
Enterprise Value
Monthly Web Traffic		33.50K	1.36K
Web Traffic Growth		2.80	-0.08
Valuation
Raised Capital		20M	235M

Metric
Revenue	9.56M	124.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit	7.46M	106.66M
EBITDA	-233.50M	-55.35M
Operating Income	-235.60M	-63.28M
Net Income	-212.22M	-66.07M
EPS	-2.91	-0.30
Diluted EPS	-2.91	-0.30
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.76	0.86
Operating Profit Margin	-23.48	-0.28
EBITDA Margin	-24.42	-0.44
Net Profit Margin	-21.04	-0.31
Return on Equity	-0.33	-0.40
Return on Assets	-0.19	-0.19
Return on Capital Employed	-0.23	-0.21

COM:AVIDITYBIOSCIENCES

Avidity Biosciences

Last Close

42.56

22/11 21:00

Market Cap

4.07B

Beta: -

Volume Today

993.16K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.46	-74.58
P/B Ratio	1.68	10.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	557.48	14.47
EV Multiple	-8.85	-20.25

Metric
Days Sales Outstanding		117.61
Days Payables Outstanding		185.33
Days Inventory Outstanding		264.91
Operating Cycle	72.73	329.52
Cash Conversion Cycle		100.07
Asset Turnover	0.02	0.61

Metric
Operating Cash Flow	-119.06M	-89.72M
Free Cash Flow	-123.29M	-90.06M
Cash Flow to Debt	-12.09	-0.77
Operating Cash Flow/Sales	-12.45	-0.41
Free Cash Flow Yield	-0.21	-0.03

Metric
Cash & Equivalents	185.08M	21.47M
Accounts Receivable		-14.30M
Inventory		12.45M
Goodwill
Debt to Capitalization	0.02	0.41
Debt to Assets	0.02	0.12
Current Ratio	11.40	5.54
Quick Ratio	15.97	4.36

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	3.52	0.09
R&D to Revenue	18.13	0.26
SG&A to Revenue	4.78	0.15